Literature DB >> 10912914

Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.

R Vidal1, M Calero, P Piccardo, M R Farlow, F W Unverzagt, E Méndez, A Jiménez-Huete, R Beavis, G Gallo, E Gomez-Tortosa, J Ghiso, B T Hyman, B Frangione, B Ghetti.   

Abstract

Amyloid beta protein deposition in cortical and leptomeningeal vessels, causing the most common type of cerebral amyloid angiopathy, is found in sporadic and familial Alzheimer's disease (AD) and is the principal feature in the hereditary cerebral hemorrhage with amyloidosis, Dutch type. The presence of the Apolipopriotein E (APOE)-epsilon4 allele has been implicated as a risk factor for AD and the development of cerebral amyloid angiopathy in AD. We report clinical, pathological and biochemical studies on two APOE-epsilon4 homozygous subjects, who had senile dementia and whose main neuropathological feature was a severe and diffuse amyloid angiopathy associated with perivascular tau neurofibrillary pathology. Amyloid beta protein and ApoE immunoreactivity were observed in leptomeningeal vessels as well as in medium-sized and small vessels and capillaries in the parenchyma of the neocortex, hippocampus, thalamus, cerebellum, midbrain, pons, and medulla. The predominant peptide form of amyloid beta protein was that terminating at residue Val40, as determined by immunohistochemistry, amino acid sequence and mass spectrometry analysis. A crown of tau-immunopositive cell processes was consistently present around blood vessels. DNA sequence analysis of the Amyloid Precursor Protein gene and Presenilin-1 (PS-1) gene revealed no mutations. In these APOE-epsilon4 homozygous patients, the pathological process differed from that typically seen in AD in that they showed a heavy burden of perivascular tau-immunopositive cell processes associated with severe amyloid beta protein angiopathy, neurofibrillary tangles, some cortical Lewy bodies and an absence of neuritic plaques. These cases emphasize the concept that tau deposits may be pathogenetically related to amyloid beta protein deposition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912914     DOI: 10.1007/s004010051186

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  23 in total

Review 1.  Don't forget astrocytes when targeting Alzheimer's disease.

Authors:  Jessica S Sadick; Shane A Liddelow
Journal:  Br J Pharmacol       Date:  2019-02-19       Impact factor: 8.739

2.  Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Authors:  John D Fryer; Kelly Simmons; Maia Parsadanian; Kelly R Bales; Steven M Paul; Patrick M Sullivan; David M Holtzman
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

3.  Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy.

Authors:  D T Winkler; L Bondolfi; M C Herzig; L Jann; M E Calhoun; K H Wiederhold; M Tolnay; M Staufenbiel; M Jucker
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

4.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.

Authors:  Cristian A Lasagna-Reeves; Diana L Castillo-Carranza; Urmi Sengupta; Jose Sarmiento; Juan Troncoso; George R Jackson; Rakez Kayed
Journal:  FASEB J       Date:  2012-01-17       Impact factor: 5.191

5.  APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics.

Authors:  M P Vitek; D J Christensen; D Wilcock; J Davis; W E Van Nostrand; F Q Li; C A Colton
Journal:  Neurodegener Dis       Date:  2012-02-09       Impact factor: 2.977

6.  Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.

Authors:  Samir Kumar-Singh; Patrick Cras; Rong Wang; John M Kros; Johan van Swieten; Ursula Lübke; Chantal Ceuterick; Sally Serneels; Krist'l Vennekens; Jean-Pierre Timmermans; Eric Van Marck; Jean-Jacques Martin; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

7.  Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease.

Authors:  J Chapuis; D Hot; F Hansmannel; O Kerdraon; S Ferreira; C Hubans; C A Maurage; L Huot; F Bensemain; G Laumet; A M Ayral; N Fievet; J J Hauw; S T DeKosky; Y Lemoine; T Iwatsubo; F Wavrant-Devrièze; J F Dartigues; C Tzourio; L Buée; F Pasquier; C Berr; D Mann; C Lendon; A Alpérovitch; M I Kamboh; P Amouyel; J C Lambert
Journal:  Mol Psychiatry       Date:  2009-02-10       Impact factor: 15.992

8.  Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.

Authors:  Dennis M Kamara; Umesh Gangishetti; Marla Gearing; Monica Willis-Parker; Liping Zhao; William T Hu; Lary C Walker
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 9.  A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review.

Authors:  Candice E Van Skike; Veronica Galvan
Journal:  Gerontology       Date:  2018-01-11       Impact factor: 5.140

Review 10.  Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models.

Authors:  Samir Kumar-Singh
Journal:  Int J Mol Sci       Date:  2009-04-23       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.